Evidence map›Paper›PMID 35635331›Full record

ArticleDiabetes, obesity & metabolism2022

Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.

Benjamin P Larkin, Long T Nguyen, Miao Hou, Sarah J Glastras, Hui Chen, Alen Faiz, Jason Chen, Rosy Wang, Carol A Pollock, Sonia Saad

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Methanol extract ofFrontiers in endocrinology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Benjamin P Larkin *Renal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.ORCID 0000-0002-7278-1112
Long T Nguyen *Renal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
Miao HouDepartment of Cardiology, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
Sarah J GlastrasRenal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
Hui ChenSchool of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, Australia.
Alen FaizSchool of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, Australia.
Jason ChenDepartment of Anatomical Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Rosy WangRenal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
Carol A PollockRenal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
Sonia SaadRenal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
The University of Sydney · AUUniversity of Technology Sydney · AURoyal North Shore Hospital · AUSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine, using a mouse model of obesity, whether low-dose hydralazine prevents obesity-related chronic kidney disease (CKD).

methodsFrom 8 weeks of age, male C57BL/6 mice received a high-fat diet (HFD) or chow, with or without low-dose hydralazine (25 mg/L) in drinking water, for 24 weeks. Biometric and metabolic variables, renal function and structural changes, renal global DNA methylation, DNA methylation profile and markers of renal fibrosis, injury, inflammation and oxidative stress were assessed.

resultsThe HFD-fed mice developed obesity, with glucose intolerance, hyperinsulinaemia and dyslipidaemia. Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect. Obesity increased renal global DNA methylation and this was attenuated by low-dose hydralazine. HFD-induced changes in methylation of individual loci were also significantly reversed by low-dose hydralazine. Obese mice demonstrated increased markers of kidney fibrosis, inflammation and oxidative stress, but these markers were not significantly improved by hydralazine.

conclusionLow-dose hydralazine ameliorated HFD-induced albuminuria and glomerulosclerosis, independent of alterations in biometric and metabolic variables or blood pressure regulation. Although the precise mechanism of renoprotection in obesity is unclear, an epigenetic basis may be implicated. These data support repurposing hydralazine as a novel therapy to prevent CKD progression in obese patients.

Indexed as

AlbuminuriaRenal Insufficiency, ChronicAnimalsDiet, High-FatDisease Models, AnimalFibrosisHydralazineInflammationKidneyMaleMiceMice, Inbred C57BLObesityHydralazinechronic kidney diseasekidney fibrosismethylationObesity

Identifiers

PMID35635331
PMCPMC9544807
OpenAlexW4281947097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.